US orthopedic and biomaterial startups still treat first-in-human as a domestic IDE problem. The calendar that actually eats a year is not the Food and Drug Administration’s 30-day Investigational Device Exemption clock under 21 CFR 812.30. It is the stacked queue: Q-Sub, a significant-risk IDE package, institutional review board review, hospital contracting, and the 12–18 month feasibility-trial wait already published on our Panama first-in-human guide. Panama’s Ministerio de Salud (MINSA) reviews high-risk investigational device protocols — including Class III implants and innovative biomaterials — under a written rulebook that puts first patient in months, not years.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the Class III / US-startup cut: MINSA’s investigational review, Panama City surgical sites, cost and timeline versus a US IDE feasibility path, and the 21 CFR 812.28 acceptance criteria that decide whether the data can enter an IDE, 510(k), De Novo, PMA, or HDE file. For insurance bands and the country table, use the first-in-human guide. For published clocks, use the Panama clinical-trials hub and the CRO in Panama page.
Two MINSA files — do not mix Class III registro with the trial
Panama runs two device desks. Confusing them is how a startup burns a quarter.
Investigational use sits with MINSA through the Dirección Nacional de Farmacia y Drogas, and with institutional bioethics committees registered with the Comité Nacional de Bioética de la Investigación (CNBI). The governing instruments are Ley 84 of 14 May 2019 and Decreto Ejecutivo No. 21 of 23 April 2026, published in Gaceta Oficial No. 30510-C, implementing Titles III and IV of that law. MINSA’s hub is Regulación de Investigación para la Salud. The live explainer is Panama’s Decreto 21 of 2026 — Type II-accredited committees for clinical trials, RESEGIS registration before start, ordinary ethics review capped at 20 business days, parallel MINSA + ethics review for high-risk protocols, and 24-hour / 15-day serious-adverse-event clocks. Those are decree clocks, not a hub median.
Commercial Class III sale is a different statute: Ley 90 of 26 December 2017, as modified by Ley 92 of 12 September 2019, regulated by Decreto Ejecutivo No. 490 of 4 October 2019. Risk class for registro sanitario follows current GHTF/IMDRF rules; the Dirección Nacional de Dispositivos Médicos is the classifying authority. The Panama MINSA market-access page already states the single Authorized Representative model. That holder role does not replace a MINSA/CNBI trial authorization, and a trial authorization is not a license to sell. Keep commercial registro off the first-in-human critical path.
When I write “Class III first-in-human trials,” I mean significant-risk investigational implants, orthopedic hardware, and biomaterials that a US reviewer would treat as Class III / PMA-directed or as a high-risk De Novo. High-risk investigational protocols are the set Decreto 21 sends through parallel MINSA + ethics review. Panama does not skip review. What it skips is a US-style IDE as a precondition to first implant.
MINSA’s investigational framework for biomaterials and Class III devices
What actually goes in, already listed on the Panama hub:
- Spanish protocol package — protocol, investigator brochure, informed consent, and insurance. Foreign-language drafts do not substitute.
- RESEGIS — Registro y Seguimiento de Investigación para la Salud. Standard projects receive a registration receipt in three business days. The public list is open, no login. It is a general health-research registry, not devices-only. Your protocol still has to be in it before start.
- Type II-accredited committee — clinical trials sit a CNBI-registered Type II committee, not an ad-hoc hospital chat.
- Parallel MINSA + ethics — high-risk work, which is where Class III implants and novel biomaterials live, does not wait for one desk to finish before the other opens.
- CNBI evaluation axes already on the FIH guide: scientific merit and design adequacy; risk-benefit and informed-consent adequacy; investigator and site infrastructure; preclinical data as a coherent safety narrative, not a GLP checklist; patient-protection measures, monitoring, and stopping rules.
I am not inventing a PAHO/WHO Level 4 badge for MINSA or CNBI. INVIMA Level 4 stays a Colombia fact. Panama’s claim is a 2026 executive decree, a public research registry, accredited Type II committees, and a MINSA desk that will read a high-risk device protocol in Spanish.
Preclinical expectations are already on the FIH guide and the early-feasibility GLP/GMP/sterility article. R&D-grade (non-GLP) data can support a Panama ethics file when the ISO 14971 file and the investigator brochure tell a coherent safety story. That is not a waiver of biocompatibility, sterility, or bench performance.
Panama City sites and surgical investigators
bioaccess® has coordinated first-in-human device studies at JCI-accredited hospitals in Panama City since the early 2010s — the public line on the hub. We do not operate a named Panamanian hospital. A city is not a site contract. Named principal investigator and named ward are a feasibility deliverable, not a sentence I will invent here.
Landscape hospitals already named on the FIH guide, as city infrastructure: Hospital Santo Tomás, Hospital Nacional, Instituto Oncológico Nacional, and Punta Pacífica (Johns Hopkins Medicine International affiliate). The public Axoft FINESSE first-in-human cases ran at The Panama Clinic — already on our FDA acceptance guide. That is a site of record for a published program. It is not a bioaccess® facility.
What a US orthopedic or biomaterial sponsor actually needs in that city:
- Qualified surgical investigators who already implant in the indication. Therapeutic areas already published on the hub: spine, orthopedic, vascular, neurotechnology. Many physicians at major centers completed US residencies or fellowships. The workforce is bilingual. That is an operating fact on the hub, not a tourism line.
- Early-feasibility n. Panama City metro is about 2 million people. Early-feasibility enrollment is typically 5–20 patients — the right size for a Class III first-in-human cohort. Rare disease or a larger n belongs in a multi-country plan (Panama plus El Salvador plus Brazil is the example already on the FIH guide).
- Investigational import. Ethics approval letter, investigator brochure, importation permit. Customs is among the more efficient in Latin America (Canal / Colón Free Zone). bioaccess® runs that file. Do not hand investigational units to a commercial distributor “because they already import.”
- Same clock as Miami. Panama City is a three-hour flight from Miami and sits on US Eastern Time.
Cost and timeline versus a US IDE feasibility path
Use numbers we have already published. Ask for a study-specific calendar.
Panama (hub and FIH guide): ethics approval 3–5 weeks, with MINSA clearance available concurrently on the high-risk track; 6–8 week average to first patient with bioaccess® coordination; 3–5 month conservative envelope including site prep; $12,000–$22,000 per patient; a 10-patient first-in-human study typically $200,000–$300,000; clinical-trial insurance typically $5,000–$15,000 by risk class and enrollment; US dollar (Balboa pegged 1:1).
United States (same pages): 6–12 months IDE + IRB on the hub table; 12–18 months to first patient on the FIH-guide country table. The statutory IDE review is 30 days. The year you lose is Q-Sub cycles, significant-risk packaging, IRB, and hospital contracting — the feasibility-trial queue this page names. Per-patient cost $40,000–$75,000. A separate IDE is required for significant-risk early feasibility. Panama requires MINSA/CNBI, not a US-style IDE, to start an investigational implant.
Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study. FDA’s Early Feasibility Studies program exists; that does not empty the US site queue. A novel biomaterial or Class III orthopedic implant with no predicate is still a legal event at a US hospital. Panama City surgical services treat it as a protocol they have run.
FDA 21 CFR 812.28 — the acceptance criteria, not a slogan
Foreign clinical data is eligible for FDA submission and review under 21 CFR 812.28 (final rule, 83 FR 7386, 21 February 2018). Eligibility is not clearance or approval. bioaccess® designs Panama studies for that conversation. We do not promise an FDA stamp.
Section 812.28(a) says FDA will accept information from a well-designed, well-conducted investigation outside the United States to support an IDE or a device marketing application (PMA under section 515, HDE under 520(m), 510(k), or De Novo) when three conditions are met:
- Good clinical practice. The rule defines GCP as a standard for design, conduct, monitoring, auditing, recording, analysis, and reporting that keeps data credible and protects subjects. GCP here includes independent ethics-committee review and approval before initiation, continuing IEC review, and documented freely given informed consent. FDA has stated that conformance with ISO 14155:2020 will generally satisfy the GCP requirement of 812.28 — already on our FDA-acceptance guide. Investigations initiated on or after 21 February 2019 must conform to the 2018 foreign-data framework.
- Supporting information in 812.28(b). For a significant-risk device as defined in 812.3(m) — the Class III / biomaterial first-in-human case — submit the full (b) set: investigators and sites; protocol and results; a statement that the investigational device is identical to the US device or a detailed comparison; valid scientific evidence under 21 CFR 860.7 if you claim safety and effectiveness; IEC identity meeting 812.3(t); consent, monitoring, and investigator GCP training.
- FDA can validate the data through an onsite inspection or other appropriate means if the agency deems it necessary. A Panama file that cannot be inspected is not an 812.28 file. Electronic data capture, device accountability, and source documents that survive an English-speaking inspector are part of the design, not a later translation job.
Section 812.28(e) is the residual clause: even when a foreign study does not fully meet paragraph (a), FDA may still accept the information if it believes the data are credible and accurate and that subject rights were adequately protected. Do not plan to live in (e). Build (a). Parallel rule already cited on the FDA-acceptance guide: 21 CFR 814.15 for foreign data in PMA applications. If the Panama protocol is meant to support a later US IDE, file a Q-Sub / Pre-Sub before you lock endpoints (written feedback in 75 calendar days). Endpoints and inclusion criteria have to be relevant to the intended US population; site standard of care has to be comparable to US practice.
Public programs already on the FDA-acceptance guide: Axoft FINESSE (first four cases at The Panama Clinic; FDA Breakthrough Device Designation in 2022); Newrotex (ethics approval in Panama; FDA Pre-Sub for a 510(k) using LATAM data); ReGelTec HYDRAFIL (Colombia early-feasibility, then FDA IDE for a US pivotal). Those names are already public. I am not adding unpublished sponsors or devices under development.
Where Class III teams burn the Panama calendar
- Treating Decreto 21 as optional. High-risk protocols get parallel MINSA + ethics. Skipping RESEGIS or sitting a committee that is not Type II-accredited is not a shortcut.
- Mixing commercial Class III registro (Ley 90 / Decreto 490) into the trial quote. Different directorate, different dossier, different importer.
- Assuming GLP certificates are the ethics question. CNBI reads the risk-benefit narrative. Bring ISO 14971 and a complete investigator brochure.
- Writing the informed consent in English and “translating later.” 812.28 wants documented consent the IEC actually approved. For FDA use, include the 21 CFR 50.25 elements. Spanish first.
- Changing the device after first implant without a comparability memo. 812.28(b)(5) is unforgiving.
- Reading this page as “leave Colombia.” We still run first-in-human work in Colombia when the device, sites, and file fit. INVIMA clocks are managed by our Colombian legal entity. Panama is a MINSA/CNBI country category. El Salvador is a lead first-in-human jurisdiction under DNM/SRS. If a protocol fits more than one, say so. We will not flip one country into the other.
If you are a US orthopedic or biomaterial startup staring at a 12–18 month domestic feasibility queue, send bioaccess® the protocol stage, device risk class, intended US filing, whether the investigational unit is identical to the US unit, and whether you also need a later MINSA commercial file. We will tell you how the MINSA/CNBI clock would run.
Explore Panama trial capabilities at bioaccessla.com/clinical-trials-panama or submit a study inquiry. Related: CRO in Panama, Decreto 21 of 2026, and the Panama first-in-human guide.